258 related articles for article (PubMed ID: 31954076)
21. Interleukin-33, endothelin-1, and inflammatory parameters in chronic spontaneous urticaria.
Kulumbegov B; Chikovani T; Gotua M; Kikodze N; Magen E
Allergy Asthma Proc; 2023 Nov; 44(6):429-435. PubMed ID: 37919851
[No Abstract] [Full Text] [Related]
22. Thyroid Autoimmunity in CSU: A Potential Marker of Omalizumab Response?
Asero R; Ferrucci SM; Calzari P; Consonni D; Cugno M
Int J Mol Sci; 2023 Apr; 24(8):. PubMed ID: 37108654
[TBL] [Abstract][Full Text] [Related]
23. Current and Future Approaches in Management of Chronic Spontaneous Urticaria Using Anti-IgE Antibodies.
Orzan OA; Popa LG; Mihai MM; Cojocaru A; Giurcăneanu C; Dorobanțu AM
Medicina (Kaunas); 2022 Jun; 58(6):. PubMed ID: 35744079
[TBL] [Abstract][Full Text] [Related]
24. Hematologic parameters as biomarkers for antihistamine and omalizumab resistance in chronic spontaneous urticaria.
Magen E; Waitman DA; Kahan NR
Allergy Asthma Proc; 2021 Jan; 42(1):e17-e24. PubMed ID: 33404397
[No Abstract] [Full Text] [Related]
25. Comparison of Omalizumab Treatment Response in Patients with Chronic Spontaneous Urticaria and Symptomatic Dermographism: A Single-Center Retrospective Study.
Cakmak ME; Yeğit OO; Öztop N
Int Arch Allergy Immunol; 2023; 184(3):236-242. PubMed ID: 36543155
[TBL] [Abstract][Full Text] [Related]
26. Effects of Omalizumab on Serum Levels of Substance P, Calcitonin Gene-Related Peptide, Neuropeptide Y, and Interleukin-31 in Patients with Chronic Spontaneous Urticaria.
Boyvadoglu C; Ulusal H; Taysı S; Ozaydin-Yavuz G; Yavuz IH; Korkmaz P; Inaloz HS
Mediators Inflamm; 2023; 2023():8087274. PubMed ID: 37795408
[TBL] [Abstract][Full Text] [Related]
27. Inflammatory cytokine levels and changes during omalizumab treatment in chronic spontaneous urticaria.
Hoşgören-Tekin S; Eyüboğlu İP; Akkiprik M; Giménez-Arnau AM; Salman A
Arch Dermatol Res; 2024 May; 316(6):261. PubMed ID: 38795119
[TBL] [Abstract][Full Text] [Related]
28. The potential pharmacologic mechanisms of omalizumab in patients with chronic spontaneous urticaria.
Chang TW; Chen C; Lin CJ; Metz M; Church MK; Maurer M
J Allergy Clin Immunol; 2015 Feb; 135(2):337-42. PubMed ID: 24948369
[TBL] [Abstract][Full Text] [Related]
29. Association Between Serum Total IgE Levels and Clinical Response to Omalizumab for Chronic Spontaneous Urticaria: A Systematic Review and Meta-Analysis.
Chuang KW; Hsu CY; Huang SW; Chang HC
J Allergy Clin Immunol Pract; 2023 Aug; 11(8):2382-2389.e3. PubMed ID: 37263348
[TBL] [Abstract][Full Text] [Related]
30. Case Report: Refractory Chronic Spontaneous Urticaria Treated With Omalizumab in an Adolescent With Crohn's Disease.
Barni S; Giovannini M; Liccioli G; Sarti L; Gissi A; Lionetti P; Mori F
Front Immunol; 2021; 12():635069. PubMed ID: 33737936
[TBL] [Abstract][Full Text] [Related]
31. Biologics for the Use in Chronic Spontaneous Urticaria: When and Which.
Maurer M; Khan DA; Elieh Ali Komi D; Kaplan AP
J Allergy Clin Immunol Pract; 2021 Mar; 9(3):1067-1078. PubMed ID: 33685605
[TBL] [Abstract][Full Text] [Related]
32. Omalizumab Updosing in Chronic Spontaneous Urticaria: an Overview of Real-World Evidence.
Metz M; Vadasz Z; Kocatürk E; Giménez-Arnau AM
Clin Rev Allergy Immunol; 2020 Aug; 59(1):38-45. PubMed ID: 32418171
[TBL] [Abstract][Full Text] [Related]
33. Effectiveness and safety of Omalizumab in the treatment of chronic spontaneous urticaria: Systematic review and meta-analysis.
Rubini NPM; Ensina LFC; Silva EMK; Sano F; Solé D
Allergol Immunopathol (Madr); 2019; 47(6):515-522. PubMed ID: 31607407
[TBL] [Abstract][Full Text] [Related]
34. Experience with Omalizumab for the treatment of chronic spontaneous urticaria in a tertiary center: real life experience.
Acar A; Gerceker Turk B; Ertam Sagduyu I; Ceylan C; Ozturk G; Unal I
Cutan Ocul Toxicol; 2020 Sep; 39(3):249-253. PubMed ID: 32597235
[TBL] [Abstract][Full Text] [Related]
35. Functional and phenotypic analysis of basophils allows determining distinct subtypes in patients with chronic urticaria.
Rauber MM; Pickert J; Holiangu L; Möbs C; Pfützner W
Allergy; 2017 Dec; 72(12):1904-1911. PubMed ID: 28585360
[TBL] [Abstract][Full Text] [Related]
36. Novel Therapeutic Approaches and Targets for Treatment of Chronic Urticaria: New Insights and Promising Targets for a Challenging Disease.
Martina E; Diotallevi F; Bianchelli T; Paolinelli M; Offidani A
Curr Pharm Biotechnol; 2021; 22(1):32-45. PubMed ID: 32603278
[TBL] [Abstract][Full Text] [Related]
37. Omalizumab in severe chronic urticaria: are slow and non-responders different?
Asero R
Eur Ann Allergy Clin Immunol; 2021 Nov; 53(6):263-266. PubMed ID: 32914943
[No Abstract] [Full Text] [Related]
38. The clinical response to omalizumab in chronic spontaneous urticaria patients is linked to and predicted by IgE levels and their change.
Ertas R; Ozyurt K; Atasoy M; Hawro T; Maurer M
Allergy; 2018 Mar; 73(3):705-712. PubMed ID: 29083482
[TBL] [Abstract][Full Text] [Related]
39. Biomarkers of chronic spontaneous urticaria and their clinical implications.
Asero R; Cugno M
Expert Rev Clin Immunol; 2021 Mar; 17(3):247-254. PubMed ID: 33496195
[No Abstract] [Full Text] [Related]
40. Effects of omalizumab on basophils: Potential biomarkers in asthma and chronic spontaneous urticaria.
Poddighe D; Vangelista L
Cell Immunol; 2020 Dec; 358():104215. PubMed ID: 33137647
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]